This trial is active, not recruiting.

Conditions adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), chronic myelomonocytic leukemia, myelodysplastic/myeloproliferative neoplasm, unclassifiable, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, refractory anemia with excess blasts
Treatments antitumor drug screening assay, chemotherapy, biological therapy
Sponsor University of Washington
Collaborator National Cancer Institute (NCI)
Start date July 2013
End date April 2015
Trial size 15 participants
Trial identifier NCT01872819, 8003, NCI-2013-01070, P30CA015704


This clinical trial uses a laboratory test called a high throughput sensitivity assay in planning treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to try to identify drugs that may be effective in killing leukemia cells for those patients who will not be cured with conventional chemotherapy. This assay will test multiple drugs simultaneously against a patient's own donated blood sample. The goal is to use this laboratory assay to best match a drug to a patient's disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
antitumor drug screening assay antitumor drug screening assays
Undergo high throughput drug sensitivity assay
chemotherapy chemo
Patients receive 1 of 160 possible interventions
biological therapy
Patients receive 1 of 160 possible interventions

Primary Outcomes

Achievability of performing individualized drug screening and initiating therapy based on the results of the drug screen for poor risk patients with relapsed or refractory AML
time frame: Up to 21 days

Secondary Outcomes

Change in the rate of complete response, defined by criteria of Cheson et al.
time frame: Baseline up to 2 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of acute myeloid leukemia by World Health Organization (WHO) criteria (except acute promyelocytic leukemia), acute leukemias of ambiguous lineage by WHO criteria, or myelodysplastic syndrome refractory anemia with excess blasts (RAEB)-2 by WHO classification or advanced myeloproliferative neoplasm with >= 10% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML)-2 by WHO classification who have failed 2 inductions at initial diagnosis or failed >= 2 salvage regimens for relapsed acute myeloid leukemia (AML) - Patients who have had a 1st remission for >= 1 year must have received cytotoxic chemotherapy as a salvage regimen - Eastern Cooperative Oncology Group (ECOG) performance status 0 - 3 - Expectation that we can obtain about 100 million blasts from blood and/or marrow (for example, circulating blast count of 5,000 or greater) - Bilirubin =< 1.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to Gilbert's syndrome, hemolysis, or hepatic infiltration by the hematologic malignancy - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum pyruvate glutamate transaminase (SPGT) (alanine aminotransferase [ALT]) =< 2.5 x IULN, unless elevation in thought to be due to hepatic infiltration by the hematologic malignancy - Alkaline phosphatase =< 2.5 X ULN - Serum creatinine =< 2.0 mg/dL - Stable or improving on appropriate antimicrobial therapy for infection, without ongoing fever - Informed consent - Willing to use contraception Exclusion Criteria: - No other concomitant treatment for leukemia - No other active cancer that requires systemic chemotherapy or radiation - Significant organ compromise that will increase risk of toxicity or mortality - Pregnancy or lactation

Additional Information

Official title Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Principal investigator Pamela Becker
Description PRIMARY OBJECTIVES: I. To obtain results from a high throughput drug sensitivity assay within 10 days, procure drug within 14 days and initiate treatment within 21 days. SECONDARY OBJECTIVES: I. To achieve a response (cytoreduction or at least partial response) greater that than expected for comparable refractory patient populations with other salvage regimens. OUTLINE: A patient receives a drug intervention based on the results of a high throughput sensitivity assay. This assay best matches a drug to the patient's disease.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by University of Washington.